Biotechnology

WuXi Biologics to Increase Manufacturing Capacity in Massachusetts

* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S. * The site is expected to employ 250 people when fully operational. WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Resea...

2024-01-08 17:52 4060

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC ("Hikma"), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health's portfolio of liquid and tissue biops...

2024-01-08 15:30 1117

2024 Trend Forecast for Cosmetic Surgery & Medical Aesthetics in Singapore

 As the demand for medical aesthetics and cosmetic surgery continues to grow, Dr Ivan Puah, a liposuction and aesthetic doctor from Amaris B. Clinic, identifies a distinct shift in consumer needs inSingapore. SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Dr Ivan Puah, Medical Director of Amaris B. Cli...

2024-01-08 09:00 400

Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023

SINGAPORE, Jan. 8, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered inSingapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year...

2024-01-08 09:00 1280

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

- Argo will receive upfront payments of $185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales. - Novartis will receive an ex-Greater China exclusive license for a Phase 1/2a stage cardiovascular asset, a worl...

2024-01-08 07:00 1156

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement onEribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countr...

2024-01-05 19:44 2353

Innovations in China's Greater Bay Area: Global Pitch Competition for Startups Announces Winners

SHENZHEN, China, Jan. 5, 2024 /PRNewswire/ -- Thousands of investors, startups, and industry enthusiasts packed the house and tuned in as the 2023 PHBS-CJBS Global Pitch Competition wrapped up. The spectacular grand final event took place in December, revealing the year's winners and other major ...

2024-01-05 18:23 4203

SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease

* Novartis to acquire SanReno's product pipeline and capabilities, including the exclusive rights forGreater China and Singapore * Transaction reflects the Novartis commitment to the Chinese market and complements existing pipeline in renal diseases. SHANGHAI, Jan. 5, 2024 /PRNewswire/ -- San...

2024-01-05 16:00 2160

UniFAHS Raises USD 1.4 Million in Seed Funding to Scale Bacteriophage Technology for Sustainable Agriculture

BANGKOK, Jan. 5, 2024 /PRNewswire/ -- UniFAHS , a trailblazing biotechnology company specialising in phage technology for sustainable agriculture and food safety, today announced it has raised overUSD 1.4 million in its seed funding round. This significant step propels the ...

2024-01-05 10:00 1934

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

* KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. * The molecule has demonstrated strong preclinical activity. Insilico present...

2024-01-05 00:19 2023

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the ...

2024-01-04 21:40 1768

OnCusp Therapeutics Raises Oversubscribed $100 Million Series A Financing to Advance Portfolio of Assets for Cancer Patients

* Financing led by Novo Holdings, OrbiMed, and F-Prime Capital, with participation by new and current investors * Proceeds to advance CUSP06, the company's antibody drug conjugate (ADC) targetingCDH6, to clinical proof-of-concept NEW YORK, Jan. 4, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc...

2024-01-04 21:11 1398

Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On December 28, 2023, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Vicagrel capsule, which is indicated to treat a range of thrombotic cardiova...

2024-01-04 21:05 1380

Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics

- AVZO-021 demonstrated a potential best-in-class preclinical potency, selectivity and pharmacokinetic profile - AVZO-021 is currently in an ongoing U.S.-based Phase 1 clinical study in advanced solid tumors - Avenzo also obtains an exclusive option to an additional preclinical program planned ...

2024-01-04 21:02 1452

GenScript, GenScript ProBio, and Legend Biotech Will Attend the 42nd JPM Healthcare Conference, Advancing Innovation and Development in the Healthcare Sector

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, will be attending the 42nd JPM Healthcare Conference held inSan Francisco, California, USA, from Ja...

2024-01-04 17:37 4181

GenScript Biotech Global Forum 2024 to Commence, Infusing New Vitality into the GCT Industry

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- On January 10, 2024, the GenScript Biotech Global Forum is set to inaugurate with grandeur during the 42nd J.P. Morgan Healthcare Conference inSan Francisco, USA. The forum, themed " Innovations and Breakthroughs Shaping Tomorrow's Cell and Gene Therapi...

2024-01-04 16:55 1234

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

* Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis. * Derived from the platform, LAE105 is a potentially first-in-class drug candidate that depletes aHSC in the fibrotic liver by harnessing innate ...

2024-01-04 12:40 1218

IASO BIO Announces New Development Partnership with Umoja Biopharma to Develop Ex Vivo and In Vivo Cell and Gene Therapies

SAN JOSE, Calif., SHANGHAI and NANJING, China, Jan. 3, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products,today announced a new set of collaborations wi...

2024-01-04 05:30 1837

GPN Vaccines Reports Positive Safety and Immunogenicity Data from its Phase 1 Trial of Gamma-PN

ADELAIDE, Australia, Jan. 3, 2024 /PRNewswire/ -- GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase...

2024-01-04 04:30 1586

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

* Company announces development of novel ionizable lipids and stabilizing components * eTurna™ delivery platform expected to improve safety, reduce immunogenicity * Customizable platform can be optimized to treat variety of cells, tissues and organs * Platform can accommodate different rou...

2024-01-03 22:00 1761
1 ... 18192021222324 ... 279